AMERSCAN MDP KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMERSCAN MDP KIT is an injectable diagnostic radiopharmaceutical approved in 1982 by GE HealthCare. The product is a kit formulation used for nuclear medicine imaging; specific indications are not disclosed in available data. It represents a legacy diagnostic modality in nuclear medicine with established clinical utility.
LOE Approaching
As a legacy diagnostic product approaching loss of exclusivity, the brand team is likely small and focused on managing mature product portfolio value rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMERSCAN MDP KIT offers limited career growth due to its mature, diagnostic-only positioning and approaching LOE. Professionals should expect roles focused on defending market share, managing compliance, and optimizing manufacturing efficiency rather than innovation or commercial expansion.
Product ManagerField Sales Representative
Worked on AMERSCAN MDP KIT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.